Last deal

$41M

Amount

Series B

Stage

07.04.2014

Date

3

all rounds

$74.4M

Total amount

date founded

Financing round

General

About Company
Alios BioPharma develops innovative treatments for viral diseases.

Industry

Sector :

Subsector :

Keywords :

Also Known As

Janssen Global Services

founded date

01.01.2006

Number of employees

Company Type

For Profit

Last funding type

Series B

IPO status

Private

Description

The company employs three platform technologies to discover and develop antiviral therapies, including small molecule activators of innate immunity antiviral pathways, phosphate protected nucleotide prodrug chemistry, and glycoprotein-engineering of interferons. Alios' proprietary chemical library of nucleoside analogs and virology-based screening systems enable the identification of distinct therapeutic products to treat viral infections such as chronic hepatitis B and C, HIV, respiratory viruses, and emerging viral diseases like SARS.
Contacts
Similar Companies
1000
Orpha Biotech

Orpha Biotech

Orpha Biotech develops innovative small molecules to treat rare diseases like systemic sclerosis and juvenile rheumatoid arthritis.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

73024 Maglie, Province of Lecce, Italy

total rounds

1

total raised

$282.57K
Virometix

Virometix

Virometix develops vaccines and immunotherapeutic drugs for infectious and chronic diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

8952 Schlieren, Switzerland

total rounds

6

total raised

$14.33M
Soligenix

Soligenix

Soligenix is a biotechnology company focused on treating rare diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Princeton, NJ, USA

total rounds

18

total raised

$57.98M
Chimerix

Chimerix

Chimerix is a biopharmaceutical company that develops novel antiviral therapeutics to improve patient care in various medical settings.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Durham, NC, USA

total rounds

14

total raised

$518.25M
M&A Details
1

Acquired by

Johnson & Johnson

announced date

30.09.2014

price

$1.75B

Financials

Funding Rounds
4
3

Number of Funding Rounds

$74.4M

Money Raised

Their latest funding was raised on 07.04.2014. Their latest investor Roche Venture Fund. Their latest round Series B

Date 
Funding Round 
Investors 
Money Raised 
Lead 
Novo Holdings

Novo Holdings

Novo Holdings is a life science investor focused on growing investment assets for scientific, social, and humanitarian purposes.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Venture Capital, Finance

Location

2900 Hellerup, Denmark

count Of Investments

303

count Of Exists

43
Novo Ventures

Novo Ventures

Novo A/S manages financial assets for Novo Nordisk Foundation and invests in life science sector.

Sector

General Industrials

Subsector

Diversified Industrials

Keywords

Financial Services, Asset Management, Finance

Location

2880 Bagsværd, Denmark

count Of Investments

60

count Of Exists

22
Novartis Venture Fund

Novartis Venture Fund

Novartis Venture Fund is a private equity and venture capital arm of Novartis AG.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Venture Capital, Biotechnology, Financial Services

Location

Basel, Switzerland

count Of Investments

201

count Of Exists

39
Co-Investors
Investors
5
3

Number of lead investors

5

Number of investors

Investor 
Lead 
Round 
Partners 
Roche Venture Fund

Roche Venture Fund

Roche Venture Fund invests in and developing innovative life science companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Basel, Switzerland

count Of Investments

83

count Of Exists

19
Carole Nuechterlein

Carole Nuechterlein

Ms. Carole L. Nuechterlein serves as a Head at Roche Venture Fund. Ms. Nuechterlein served as a Senior Vice President at SangStat since 2001. She joined the SangStat in October 1998 as Vice President & General Counsel. She served at Roche Bioscience as Director of Legal Affairs. Ms. Nuechterlein also worked at Syntex Corporation prior to its acquisition by Roche Holding Ltd. in 1994. As Director of Legal Affairs, Ms. Nuechterlein specialized in transactional work, representing Roche in several divestitures of Syntex assets and in the negotiation of a number of research collaboration and licensing agreements. Prior to that, she was in the San Francisco office of Skadden Arps Slate Meagher & Flom, specializing in mergers and acquisitions. She served as a Director of Alios Biopharma, Inc. Ms. Nuechterlein holds her undergraduate degree from Valparaiso University (with honors) and her J.D. from the University of Michigan (with honors).

current job

SangStat
SangStat
Novo Ventures

Novo Ventures

Novo A/S manages financial assets for Novo Nordisk Foundation and invests in life science sector.

Sector

General Industrials

Subsector

Diversified Industrials

Keywords

Financial Services, Asset Management, Finance

Location

2880 Bagsværd, Denmark

count Of Investments

60

count Of Exists

22
Heath Lukatch

Heath Lukatch

Heath Lukatch is a Founder & Managing Partner at Red Tree Venture Capital.Heath attended University of California and Stanford university.

current job

Red Tree Venture Capital
Red Tree Venture Capital
Novartis Venture Fund

Novartis Venture Fund

Novartis Venture Fund is a private equity and venture capital arm of Novartis AG.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Venture Capital, Biotechnology, Financial Services

Location

Basel, Switzerland

count Of Investments

201

count Of Exists

39
Campbell Murray

Campbell Murray

current job

Intima Biosciences
Intima Biosciences

People

Founders
3

Leonid Beigelman

Leonid Beigelman is the Cheif Scientific Officer at Alios BioPharma.

current job

Alios BioPharma
Alios BioPharma

organization founded

2

Leonid Beigelman

Lawrence Blatt
Lawrence Blatt

Lawrence Blatt

Lawrence M. Blatt is the chief executive officer of Aligos Therapeutics. Lawrence M. Blatt attended University of La Verne.

current job

Aligos Therapeutics
Aligos Therapeutics

organization founded

3

Lawrence Blatt

John Donovan

current job

Tolerion
Tolerion

organization founded

1

John Donovan

Employee Profiles
14
Cheng Kao

Cheng Kao

Senior Research Fellow

Amanda Bianculli

Senior administative assistant

Laura Gardner

Executive assistant r and d

Anh Truong

Senior scientist at alios biopharma

Leonid Beigelman

Founder, Chief Scientific Officer

Robert Planting

Manager, ehs and lab

Jin Hong

Scientific director

John Donovan

Founder, Chief Business Officer

Activity

Recent News
0